Xylometazoline
As of the edition of 20 October 2026, Xylometazoline is a small molecule: marketed, first approved in 1957 (ES); acts on ADRA1A, ADRA1B and ADRA1D and 3 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1961
- Kind
- Small molecule
- Brand name
- Amidrin
- First approved
- 1 August 1957 (ES)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- HALEON CANADA ULC; 2 holders in all
- Registered trials
- 12, 0 stopped early
- Disease areas
- Lungs and airways; Ear, nose and throat; Infections; Immune system; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 7 | 6 | 0 | 0 |
| Phase 3 | 2 | 1 | 1 | 0 |
| Phase 4 | 3 | 1 | 0 | 0 |
| All trials | 12 |